OABI Stock Analysis: Buy, Sell, or Hold?
OABI - OmniAb, Inc. Common Stock
$2.44
0.10 (4.51%)
▲
5d:
+20.54%
30d:
-8.11%
90d:
+45.81%
BUY
HIGH Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 05, 2026
Get Alerted When OABI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: OABI shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
✅ BUY SIGNAL: OABI shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
In-depth Analysis How we analyze
Valuation Analysis: OABI is currently trading at $2.44, which is considered fair relative to its 30-day fair value range of $2.24 to $2.62.
Technical Outlook: Technically, OABI is in a uptrend. Immediate support is located at $2.26, while resistance sits at $2.79. The stock is showing strong short-term momentum, up 4.5% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $7.33 (+214.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, OABI is in a uptrend. Immediate support is located at $2.26, while resistance sits at $2.79. The stock is showing strong short-term momentum, up 4.5% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $7.33 (+214.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$2.24 -
$2.62
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
84.2%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4.5%)
- BULLISH: Trading 214.7% below Wall St target ($7.33)
Trading Range Analysis
30-Day Trading Range
$2.24 -
$2.62
Current vs Trading Range
FAIR
Expected Move (7 Days)
±$0.17
(7.0%)
Support & Resistance Levels
Support Level
$2.26
Resistance Level
$2.79
Current Trend
Uptrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-7.22
Wall Street Target
$7.33
(+214.7%)
Revenue Growth (YoY)
247.3%
Profit Margin
-187.6%
Share & Embed Analysis
Last updated: June 24, 2026 10:47 AM ET
Data refreshes hourly during market hours. Next update: 11:47 AM
Data refreshes hourly during market hours. Next update: 11:47 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is OABI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
9
Sells
Net
INSIDERS SELLING
Recent Transactions
Charles S Berkman
SELL
7157 shares
2026-04-07
Kurt A Gustafson
SELL
6913 shares
2026-04-07
Matthew W Foehr
SELL
19244 shares
2026-04-07
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$833 | 67 BUY |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$105 | 64 BUY |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 61 BUY |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$28 | 65 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$102 | 65 BUY |
